Ignite Creation Date:
2025-12-25 @ 5:04 AM
Ignite Modification Date:
2025-12-26 @ 4:06 AM
Study NCT ID:
NCT03430518
Status:
COMPLETED
Last Update Posted:
2020-08-05
First Post:
2018-02-06
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
Sponsor:
Amy Tiersten
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-05-17
Start Date Type:
ACTUAL
Primary Completion Date:
2020-02-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-02-10
Completion Date Type:
ACTUAL
First Submit Date:
2018-02-06
First Submit QC Date:
None
Study First Post Date:
2018-02-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-08-04
Last Update Post Date:
2020-08-05
Last Update Post Date Type:
ACTUAL